Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trillium Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (40)	1/27/2016 9:37:58 PM
From: tuck	Respond to of 294

Fluorinov: lots of NPS people. The CSO was involved in the mGluR program, which fizzled. Some of their stuff looks interesting, though one would think Trillium would at least out-license the the CNS programs. Irreversible oral proteasome inhibotor with 6x the therapeutic index of carfilzomib. No idea what competition is doing here. Survivin inhibitor with better ADME than competitors (such as, presumably, Lilly/Ionis, which fizzled). Irreverisble oral EGFR inhibitor fluorinated in special ways that hits the T790M mutant. Though I'm thinking there are other good competitors in this area. Cheers, Tuck

To: tuck who wrote (40)	10/28/2016 3:06:06 PM
From: tuck	Respond to of 294

BET inhibitor update: Another player I found is in the optimization stage: Epigenetix And an even earlier stage effort from FORMA Threapeutics: FT-1101: A Structurally Distinct Pan-BET Bromodomain Inhibitor with Activity in Preclinical Models of Hematologic Malignancies Both private. Here's an abstract specifically about Trillium's FV-281. The Highly Potent Bromodomain (BRD) Inhibitor FV-281 Displays Preclinical Efficacy in Acute Myeloid Leukemia (AML) And from the Juno thread (H/T to Peter and Rick) a reason for CAR-T players to give Trillium (or its competitors in the space) a ring about this program: BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models Note that the authors of this latter study are almost entirely from Princess Margaret, where both Trillium and Fluorinov can trace heritage. Cheers, Tuck